Oriola Corp Class B · OMXHEX:ORIOLA
Oriola Corp Class B — Q3 2020 Earnings Presentation
23 slides from Oriola Corp Class B's earnings presentation, Oct 23, 2020
Slide 1: Oriola Corporation Interim report January – September 2020
Oriola Corporation Interim report January – September 2020
Slide 2: Q3 2020 highlights
Q3 2020 highlights ”Pandemic continued to impact business significantly; progress in several areas” • Second wave of COVID-19 causes ambiguity • Demand for medicines remained lower than normal and cost to serve increased • Online sales grew faster than the market • Covid-driven adjacent services dev
Slide 3: Good progress in service sales & development
Good progress in service sales & development • Consumer pharmacy online sales growth 71% - new product categories launched • Click & Collect service available in all pharmacies • COVID-19 antibody tests in pharmacies to help society and people • National medicine stock service in Sweden • More effic
Slide 4: Key figures
Key figures continuing operations Invoicing Net sales Adjusted EBIT1 EUR million EUR million EUR million 4 000 3 733 1 800 1 721 70 3 518 1 589 1 552 3 500 3 364 3 336 1 600 1 528 60 58.7 1 400 3 000 50 1 200 2 500 439 39.0 917 915 429 40 812 844 1 000 383 378 370 34.4 2 000 823 16.2 800 30 9.4 1 50
Slide 5: Adjusted EBIT
Adjusted EBIT Adjusted EBIT1 Adjusted EBIT development1 EUR million EUR million 10 10 -0.7 8 8 -2.2 1.2 -1.0 6 6 9.1 9.1 4 4 6.9 6.3 6.3 5.6 2 3.7 2 2.1 0 -0.3 0 2019 Consumer Pharma Retail Group 2020 2019 2019 2019 2019 2020 2020 2020 Q3 items Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 1The figures for Q1-Q3 2019 hav
Slide 6: Operating environment & Oriola
& Oriola Operating environment
Slide 7: Consumer markets
Consumer markets Online share of Swedish Market shares Pharmacy 388 market Pharmacy387 market 397 18% 16% 396397 14% 326327 4.6 BEUR 4.6 BEUR 12% 10% 187188 8% 6% 79 79 4% 48 Oriola/Kronans Apotek 17% (17%) Rx 74% (74%) 2% Apoteket 30% (32%) OTC 8% (9%) 0% Apotek Hjärtat & CURA 31% (31%) TG 18% (17%
Slide 8: Wholesale markets
Wholesale markets Pharmaceutical market value growth in Q3: Finland -0.2% and Sweden +3.0% Finland Wholesale Sweden Wholesale 2.8 BEUR 4.6 BEUR Oriola 42% (46%) Oriola 47% (42%) Others 58% (54%) Others 53% (58%) Market shares are Q3 figures and Source: LTK and Oriola estimate Source: IQVIA and Oriol
Slide 9: Retail markets
Retail markets Market share dose dispensing TG/OTC products supply for pharmacies in Sweden Sweden Total 230,000 Oriola 43% (43%) Others 57% (57%) 25% patients from the total market of EUR 1.2 billion Market share is Q3 figure and market size rolling 12 month figure Finland Staffing services in Finl
Slide 10: Business Area reviews Q3 2020
Business Area reviews Q3 2020
Slide 11: Three customer-centric business areas
Three customer-centric business areas Consumer business area Pharma business area Retail business area Retail services and products for consumer Tailored logistics, expert and advisory A wide range of health and wellbeing health and wellbeing in Sweden in services for pharmaceutical companies, produ
Slide 12: Consumer Q3 2020
Consumer Q3 2020 • Net sales increased by 1.2% to 184.8 M€ Adjusted EBIT1 EUR million in constant currency 6 • Strong growth continued in Kronans Apotek’s online sales (+71% vs market +53%) 5 • Pharmacy volumes decreased especially in 4 shopping centres 3 5.4 • Share of OTC and traded goods of net s
Slide 13: Pharma Q3 2020
Pharma Q3 2020 Adjusted EBIT EUR million • Net Sales increased by 1.4% to 234.7 M€, and decreased by 0.5% in constant 6 currency 5 • Pharmaceuticals sales slowed down due 4 to pandemic and continued elective healthcare scale down 3 5.2 4.7 • Profit negatively impacted by changes in 2 4.2 3.5 3.6 cus
Slide 14: Retail Q3 2020
Retail Q3 2020 • Net sales increased by 4.6% to Adjusted EBIT EUR million 118.8 M€, and increased by 1.9% in constant currency • Improved profitability in dose dispensing 1 impacted results positively 1.5 • Demand for products related to pandemic remained active 0.2 0.3 0.2 0 • High operations costs
Slide 15: Financial review Q3 2020
& Oriola Financial review Q3 2020
Slide 16: Invoicing and net sales
Invoicing and net sales Invoicing Invoicing Net sales EUR million EUR million 1 000 500 900 450 800 400 700 350 600 300 500 942 917 979 965 915 250 460 894 898 448 429 447 436 439 400 979 200 397 300 150 200 100 100 50 0 0 2019 2019 2019 2019 2020 2020 2020 2019 2019 2019 2019 2020 2020 2020 Q1 Q2 Q
Slide 17: Adjusted EBIT
Adjusted EBIT Adjusted EBIT1 Adjusted EBIT development1 EUR million EUR million 10 10 -0.7 8 8 -2.2 1.2 -1.0 6 6 9.1 9.1 4 4 6.9 6.3 6.3 5.6 2 3.7 2 2.1 0 -0.3 0 2019 Consumer Pharma Retail Group 2020 2019 2019 2019 2019 2020 2020 2020 Q3 items Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 1The figures for Q1-Q3 2019 hav
Slide 18: Profit for the period and earnings per share
Profit for the period and earnings per share Profit for the period1 Earnings per share1 EUR million EUR 6 0.06 4 0.04 5.1 2 4.5 0.02 3.7 0.02 0.03 1.7 2.0 0.02 0.01 0.01 0 -0.2 0.00 0.00 -0.01 -1.6 -2 -0.02 2019 2019 2019 2019 2020 2020 2020 2019 2019 2019 2019 2020 2020 2020 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1
Slide 19: Cash flow
Cash flow Quarterly net cash flow from operating activities Q3 YTD 2020 change in cash EUR million EUR million 80 200 60 150 40 70 48 97.0 20 100 27 13 9 12.6 157.6 0 -1 4 -22.8 50 -25 -20 70.8 -40 0 2018 2019 2019 2019 2019 2020 2020 2020 Cash Q4 2019 Operating Investing Financing Cash Q3 2020 Q4 Q
Slide 20: Net Interest-Bearing Debt
Net Interest-Bearing Debt Net interest-bearing debt 30 Sep 30 Sep 31 Dec EUR million EUR million 2020 2019 2019 250 Bank loans 126.5 57.2 57.8 (syndicated Bank & term) 200 Commercial papers 87.1 35.0 35.0 Advance payment from 20.1 21.8 13.2 pharmacies 150 Lease liabilities 80.8 84.2 84.3 100 199 Ca
Slide 21: Q3 2020 Key take-aways
Q3 2020 Key take-aways ”Pandemic continued to impact business significantly; progress in several areas” Second wave of Demand for Online sales grew Enköping ramp-up Delivering our COVID-19 causes medicines lower faster than the completed during purpose ambiguity than normal and market Q4, focus shif
Slide 22: Outlook for 2020
Outlook for 2020 Adjusted EBIT on a constant currency basis stays on the same level or increases from the 2019 level Oriola’s business outlook for 2020 is based on external market forecasts, agreements with pharmaceutical companies and pharmacies, and management assessments. 22
Slide 23: Thank you!
Thank you! IR contact: Katja Graff, Treasury & IR Manager, +358 10 429 013 katja.graff@oriola.com